U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No. 001-37370 MY SIZE, INC. (Exact name of registrant as specified in its charter) Delaware 51-0394637 (I.R.S. Employer (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from to Commission file number: 001-42385 BOLD EAGLE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, INC. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to CANTOR EQUITY PARTNERS I, INC. (Exact name of registrant as specified in its charter) Cayman Islands 001-42464 98-1576503 (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to CANTOR EQUITY PARTNERS II, INC. (Exact name of registrant as specified in its charter) Cayman Islands 001-42630 98-1576521 (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42173 Launch One Acquisition Corp. (Exact name of registrant as specified in its charter) Cayman Islands 98-1781481 (State or ot ...

For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's telephone number, including area code) Not Applicable (Former name, former address and former fiscal year, if changed since last report) For the transition period from to Commi ...

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., August 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today reported its second quarter 2025 o ...

财务数据关键指标变化：收入和利润 - 第四季度净销售额为1.52亿美元，同比增长900万美元或6.3%[5] - 2025财年全年销售额为5.651亿美元，毛利率为15.0%，同比提升280个基点[4] - 第四季度归属于Strattec的净利润为830万美元，摊薄后每股收益为2.01美元[4][9] - Strattec第四季度GAAP净收入为416.5万美元，全年GAAP净收入为1631.3万美元[23] - 第四季度调整后净亏损32.9万美元，全年调整后净收入1233.5万美元[23] - 第四季度GAAP每股收益1.05美元，全年GAAP每股收益4.07美元[23] - 第四季度调整后每股亏损0.08美元，全年调整后每股收益3.08美元[23] 财务数据关键指标变化：成本和费用 - 第四季度毛利率为16.7%，较去年同期的13.0%提升了370个基点[4][6] - 公司执行了800万美元的新年度定价并削减了500万美元的成本[3] - 增量关税影响估计在500万至700万美元之间[3] - 重组相关费用第四季度33.1万美元，全年39.8万美元[23] - FY23一次性价格回收净调整影响第四季度799.3万美元[23] - 高管转型成本第四季度125.7万美元，全年277.8万美元[23] - 业务转型成本全年102.7万美元[23] - 非控股权益调整影响第四季度127.2万美元[23] 财务数据关键指标变化：现金流和资本支出 - 第四季度运营现金流为3020万美元，全年运营现金流为7170万美元[4][10] - 2025财年经营活动现金流为7167.7万美元，较上年同期的1226.5万美元增长484%[21] - 2025财年资本支出为715.6万美元，较上年同期的978.8万美元减少26.9%[21] 财务数据关键指标变化：资产和存货 - 现金及等价物为8460万美元，较上季度增加2250万美元[11] - 现金及现金等价物大幅增加至8457.9万美元，较上年同期的2541万美元增长233%[20][21] - 总资产从3.64亿美元增至3.91亿美元，同比增长7.5%[20] - 存货净额从8164.9万美元降至6470.1万美元，减少20.7%[20] - 预生产成本从2217.3万美元大幅下降至865.7万美元，减少61%[20] - 应收账款净额从9929.7万美元微增至1.02亿美元，增长2.8%[20] - 留存收益从2.51亿美元增至2.69亿美元，增长7.5%[20] - 合资企业循环信贷协议借款从1300万美元减少至800万美元[11] 财务数据关键指标变化：盈利能力指标 - 第四季度调整后EBITDA为1300万美元，占销售额的8.5%[4][9] - 2025财年调整后EBITDA为4375.8万美元，占调整后净销售额的7.7%[22] - 2025财年第四季度调整后EBITDA利润率为8.5%，较上年同期9.6%有所下降[22] 其他财务数据 - 加权平均流通股数第四季度397.4万股，全年400.4万股[23]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Commission File Number 001-40766 Lightwave Logic, Inc. (Exact name of registrant as specified in its charter) Nevada FORM 10-Q ____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...